Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

US pharma giant Pfizer won a bidding war to acquire obesity drug developer Metsera, beating back an offer from Danish rival ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Explore the fierce competition between Novo Nordisk and Pfizer as they vie for Metsera amidst a booming obesity drug market.

Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

Tuesday's quarterly earnings release underscored the necessity for new revenue drivers. Although Pfizer exceeded analyst expectations with earnings of $0.87 per share against projections of $0.79, ...

Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in ...

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called zimislecel for type 1 diabetes (T1D), and the therapy is showing the ...

First in the industry sustainability bond provides opportunities to invest in projects supporting environmental sustainability and health of vulnerable populations Supports United Nations Sustainable ...